Literature DB >> 21108954

The role of fragile X mental retardation protein in major mental disorders.

S Hossein Fatemi1, Timothy D Folsom.   

Abstract

Fragile X mental retardation protein (FMRP) is highly enriched in neurons and binds to approximately 4% of mRNAs in mammalian brain. Its loss is a hallmark of fragile X syndrome (FXS), the most common form of mental retardation. In this review we discuss the mutation in the fragile X mental retardation-1 gene (FMR1), that leads to FXS, the role FMRP plays in neuronal cells, experiments from our own laboratory that demonstrate reductions of FMRP in additional psychiatric disorders (autism, schizophrenia, bipolar disorder, and major depressive disorder), and potential therapies to ameliorate the loss of FMRP. This article is part of a Special Issue entitled 'Trends in neuropharmacology: in memory of Erminio Costa'.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21108954      PMCID: PMC3078953          DOI: 10.1016/j.neuropharm.2010.11.011

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  80 in total

Review 1.  Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function.

Authors:  Gary J Bassell; Stephen T Warren
Journal:  Neuron       Date:  2008-10-23       Impact factor: 17.173

2.  Fragile X-associated tremor/ataxia syndrome--an older face of the fragile X gene.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Nat Clin Pract Neurol       Date:  2007-02

3.  Localization of FMRP-associated mRNA granules and requirement of microtubules for activity-dependent trafficking in hippocampal neurons.

Authors:  L N Antar; J B Dictenberg; M Plociniak; R Afroz; G J Bassell
Journal:  Genes Brain Behav       Date:  2005-08       Impact factor: 3.449

4.  Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation.

Authors:  I J Weiler; S A Irwin; A Y Klintsova; C M Spencer; A D Brazelton; K Miyashiro; T A Comery; B Patel; J Eberwine; W T Greenough
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

5.  Association of FMRP with ribosomal precursor particles in the nucleolus.

Authors:  R Willemsen; C Bontekoe; F Tamanini; H Galjaard; A Hoogeveen; B Oostra
Journal:  Biochem Biophys Res Commun       Date:  1996-08-05       Impact factor: 3.575

6.  Immunocytochemical and biochemical characterization of FMRP, FXR1P, and FXR2P in the mouse.

Authors:  C E Bakker; Y de Diego Otero; C Bontekoe; P Raghoe; T Luteijn; A T Hoogeveen; B A Oostra; R Willemsen
Journal:  Exp Cell Res       Date:  2000-07-10       Impact factor: 3.905

7.  Developmental expression of FMRP in the astrocyte lineage: implications for fragile X syndrome.

Authors:  Laura K K Pacey; Laurie C Doering
Journal:  Glia       Date:  2007-11-15       Impact factor: 7.452

8.  The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation.

Authors:  D Devys; Y Lutz; N Rouyer; J P Bellocq; J L Mandel
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

9.  Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia.

Authors:  Carlotta E Duncan; Maree J Webster; Debora A Rothmond; Sabine Bahn; Michael Elashoff; Cynthia Shannon Weickert
Journal:  J Psychiatr Res       Date:  2010-01-25       Impact factor: 4.791

10.  Expression of GABA(B) receptors is altered in brains of subjects with autism.

Authors:  S Hossein Fatemi; Timothy D Folsom; Teri J Reutiman; Paul D Thuras
Journal:  Cerebellum       Date:  2009-03       Impact factor: 3.847

View more
  34 in total

Review 1.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

2.  Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder.

Authors:  Weerasak Chonchaiya; Jacky Au; Andrea Schneider; David Hessl; Susan W Harris; Meredith Laird; Yi Mu; Flora Tassone; Danh V Nguyen; Randi J Hagerman
Journal:  Hum Genet       Date:  2011-10-15       Impact factor: 4.132

3.  A novel assay for evaluating fragile X locus repeats.

Authors:  Karl Adler; J Kent Moore; Galina Filippov; Shaoping Wu; Jon Carmichael; Mack Schermer
Journal:  J Mol Diagn       Date:  2011-07-26       Impact factor: 5.568

4.  Neuregulin 1-induced AKT and ERK phosphorylation in patients with fragile X syndrome (FXS) and intellectual disability associated with obstetric complications.

Authors:  Tamás Kovács; Boglárka Bánsági; Oguz Kelemen; Szabolcs Kéri
Journal:  J Mol Neurosci       Date:  2014-02-23       Impact factor: 3.444

5.  Fragile X Mental Retardation Protein expression in the retina is regulated by light.

Authors:  E M Guimarães-Souza; O Perche; C W Morgans; R M Duvoisin; K C Calaza
Journal:  Exp Eye Res       Date:  2015-12-21       Impact factor: 3.467

Review 6.  Early identification of autism in fragile X syndrome: a review.

Authors:  L M McCary; J E Roberts
Journal:  J Intellect Disabil Res       Date:  2012-09-14

7.  Effects of stimulus salience on touchscreen serial reversal learning in a mouse model of fragile X syndrome.

Authors:  Price E Dickson; Beau Corkill; Eric McKimm; Mellessa M Miller; Michele A Calton; Daniel Goldowitz; Charles D Blaha; Guy Mittleman
Journal:  Behav Brain Res       Date:  2013-06-04       Impact factor: 3.332

8.  Epilepsy drives autism in neurodevelopmental disorders.

Authors:  Randi J Hagerman
Journal:  Dev Med Child Neurol       Date:  2013-02       Impact factor: 5.449

9.  Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice.

Authors:  Shervin Gholizadeh; Jason Arsenault; Ingrid Cong Yang Xuan; Laura K Pacey; David R Hampson
Journal:  Neuropsychopharmacology       Date:  2014-07-07       Impact factor: 7.853

10.  Psychosis and catatonia in fragile X: Case report and literature review.

Authors:  Tri Indah Winarni; Andrea Schneider; Neera Ghaziuddin; Andreea Seritan; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.